Trial Profile
An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf) Plus Cobimetinib (Cotellic) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms RadioCoBRIM
- 12 Sep 2023 Status changed from active, no longer recruiting to discontinued.
- 08 Apr 2021 Planned End Date changed from 1 Jul 2022 to 31 Dec 2022.
- 08 Apr 2021 Planned primary completion date changed from 1 Jul 2022 to 31 Dec 2022.